Septerna (SEPN) Stock Sees Fair Value Lift As Analysts Raise SEP 479 Expectations

Mitch Lawler

Thu, November 12, 2026 at 10:17 PM EST 3 min read

Septerna’s refreshed analyst narrative now anchors around a higher fair value estimate, moving from about US$54.22 to about US$59.22. Recent research links this lift in target valuation to a cluster of higher price targets that lean on upcoming SEP-479 and platform milestones through 2027. As you read on, you will see how to track these shifting targets and what they could mean for following the evolving Septerna story over time.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Septerna.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Several firms, including Guggenheim, Wells Fargo, Stifel and JPMorgan, have outlined higher price targets for Septerna, and their recent valuation work is centered on upcoming SEP-479 and platform milestones through 2027.
Guggenheim highlights potential product and platform validation in 2027 and links this directly to its higher target range for Septerna.
Wells Fargo points to its cross-program, preclinical, commercial and valuation analysis of SEP-479 and describes this work as a key driver for its updated Septerna target.

🐻 Bearish Takeaways

All four firms tie their views to successful execution on SEP-479 and broader platform goals by 2027, so outcomes from early clinical data and development timelines remain important sources of uncertainty for Septerna.
The focus on a concentrated asset and program cluster creates execution risk, since any delay or weaker than expected data around SEP-479 or the underlying platform could put pressure on valuation relative to current analyst targets.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

We’ve flagged 2 risks for Septerna. See which could impact your investment.

How This Changes the Fair Value For Septerna

Fair value was raised from about US$54.22 to about US$59.22 for Septerna.
Revenue growth is now assumed to decline 21.51% compared with a prior 21.11% decline.
Profit margin is now set at about 18.96% compared with about 17.11% before.
Future P/E is now about 471.2x compared with about 425.9x in the earlier model.
The discount rate remains effectively unchanged at about 7.24%.

Never Miss an Update: Follow The Narrative

Narratives connect Septerna’s scientific story to a financial forecast and fair value that refresh as new information arrives. They help you see how clinical milestones, partnerships and platform progress line up with analysts’ expectations over time.